JP2017528460A - 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド - Google Patents

不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド Download PDF

Info

Publication number
JP2017528460A
JP2017528460A JP2017512975A JP2017512975A JP2017528460A JP 2017528460 A JP2017528460 A JP 2017528460A JP 2017512975 A JP2017512975 A JP 2017512975A JP 2017512975 A JP2017512975 A JP 2017512975A JP 2017528460 A JP2017528460 A JP 2017528460A
Authority
JP
Japan
Prior art keywords
cancer
cell
tumor
lymphoma
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528460A5 (enExample
Inventor
チェスワース，リチャード
アレーネ クルーナン フォリー，メーガン
アレーネ クルーナン フォリー，メーガン
ウェイン クンツ，ケヴィン
ウェイン クンツ，ケヴィン
ヘレン ミッチェル，ローナ
ヘレン ミッチェル，ローナ
シー． ペッター，ラッセル
シー． ペッター，ラッセル
エリック シュワルツ，カール
エリック シュワルツ，カール
Original Assignee
エピザイム インコーポレイテッド
エピザイム インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピザイム インコーポレイテッド, エピザイム インコーポレイテッド filed Critical エピザイム インコーポレイテッド
Publication of JP2017528460A publication Critical patent/JP2017528460A/ja
Publication of JP2017528460A5 publication Critical patent/JP2017528460A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017512975A 2014-09-10 2015-09-09 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド Pending JP2017528460A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048760P 2014-09-10 2014-09-10
US62/048,760 2014-09-10
PCT/US2015/049231 WO2016040511A1 (en) 2014-09-10 2015-09-09 Isoxazole carboxamides as irreversible smyd inhibitors

Publications (2)

Publication Number Publication Date
JP2017528460A true JP2017528460A (ja) 2017-09-28
JP2017528460A5 JP2017528460A5 (enExample) 2018-10-25

Family

ID=55459533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512975A Pending JP2017528460A (ja) 2014-09-10 2015-09-09 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド

Country Status (6)

Country Link
US (2) US10179773B2 (enExample)
EP (1) EP3193606B1 (enExample)
JP (1) JP2017528460A (enExample)
AU (1) AU2015315180A1 (enExample)
CA (1) CA2960279A1 (enExample)
WO (1) WO2016040511A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017528464A (ja) * 2014-09-10 2017-09-28 エピザイム，インコーポレイティド 置換ピペリジン化合物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017526706A (ja) 2014-09-10 2017-09-14 エピザイム，インコーポレイティド イソオキサゾールカルボキサミド化合物
AU2015315171A1 (en) 2014-09-10 2017-03-16 Epizyme, Inc. Substituted cyclohexylamine compounds
KR102496364B1 (ko) 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Ｓｍｙｄ 억제제
JP2017528460A (ja) * 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド
CN114246851B (zh) * 2021-11-09 2024-01-26 澳门科技大学 一种组蛋白甲基转移酶smyd3小分子抑制剂的合成方法及用途
CN115998869B (zh) * 2022-09-23 2025-08-05 华中科技大学同济医学院附属同济医院 组蛋白甲基转移酶smyd2在制备防治血管损伤后内膜新生导致再狭窄的药物中的应用
IT202200021138A1 (it) * 2022-10-13 2024-04-13 Istituto Di Ricovero E Cura A Carattere Scient Saverio De Bellis Formulati farmaceutici con attività inibente le metiltrasferasi istoniche per il trattamento di patologie neoplastiche

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1528745A (zh) * 2003-10-21 2004-09-15 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其制备方法
JP2006518368A (ja) * 2003-02-21 2006-08-10 ファイザー・インク プロテインキナーゼ阻害剤としてのｎ−ヘテロシクリル置換アミノチアゾール誘導体
JP2008528465A (ja) * 2005-01-21 2008-07-31 アステックス・セラピューティクス・リミテッド Ｃｄｋおよびｇｓｋの阻害のためのピラゾール誘導体
WO2008137834A2 (en) * 2007-05-04 2008-11-13 Osi Pharmaceuticals, Inc. Crystal structure of smyd3 protein
WO2013043826A1 (en) * 2011-09-21 2013-03-28 Abbvie Inc. Tricyclic compounds useful as protein kinase inhibitors
WO2016040515A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Substituted piperidine compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017526706A (ja) * 2014-09-10 2017-09-14 エピザイム，インコーポレイティド イソオキサゾールカルボキサミド化合物
AU2015315171A1 (en) * 2014-09-10 2017-03-16 Epizyme, Inc. Substituted cyclohexylamine compounds
KR102496364B1 (ko) 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Ｓｍｙｄ 억제제
JP2017528460A (ja) * 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド
US20170247326A1 (en) 2014-09-10 2017-08-31 Epizyme, Inc. Substituted Pyrrolidine Carboxamide Compounds
US20170253601A1 (en) 2014-09-10 2017-09-07 Epizyme, Inc. Substituted Pyrrolidine Compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518368A (ja) * 2003-02-21 2006-08-10 ファイザー・インク プロテインキナーゼ阻害剤としてのｎ−ヘテロシクリル置換アミノチアゾール誘導体
CN1528745A (zh) * 2003-10-21 2004-09-15 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其制备方法
JP2008528465A (ja) * 2005-01-21 2008-07-31 アステックス・セラピューティクス・リミテッド Ｃｄｋおよびｇｓｋの阻害のためのピラゾール誘導体
WO2008137834A2 (en) * 2007-05-04 2008-11-13 Osi Pharmaceuticals, Inc. Crystal structure of smyd3 protein
WO2013043826A1 (en) * 2011-09-21 2013-03-28 Abbvie Inc. Tricyclic compounds useful as protein kinase inhibitors
WO2016040515A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Substituted piperidine compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017528464A (ja) * 2014-09-10 2017-09-28 エピザイム，インコーポレイティド 置換ピペリジン化合物

Also Published As

Publication number Publication date
CA2960279A1 (en) 2016-03-17
US10179773B2 (en) 2019-01-15
EP3193606B1 (en) 2020-06-24
WO2016040511A1 (en) 2016-03-17
EP3193606A1 (en) 2017-07-26
US20180230110A1 (en) 2018-08-16
US20190241529A1 (en) 2019-08-08
EP3193606A4 (en) 2018-04-11
AU2015315180A1 (en) 2017-03-16
US10669243B2 (en) 2020-06-02

Similar Documents

Publication Publication Date Title
JP2017528460A (ja) 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド
AU2025204601A1 (en) Substituted indoles and methods of use thereof
US20230172914A1 (en) Biomarker-based therapeutic composition
CN104540500B (zh) 人ezh2抑制剂及其应用方法
EP3193604B1 (en) Substituted n-(pyrrolidin-3-yl)isoxazole-3-carboxamide compounds
JP2017528461A (ja) 置換ピロリジンカルボキサミド化合物
US10428029B2 (en) Isoxazole carboxamide compounds
US20150152088A1 (en) Alkynyl heteroaromatic compound and use thereof
US20240409528A1 (en) Binders of cereblon and methods of use thereof
US20250263404A1 (en) Aminopyridines as activators of pi3 kinase
JP2020520381A (ja) ピロロピリジン誘導体化合物、その製造方法及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防または治療のための薬学的組成物
US10106510B2 (en) Substituted isoxazoles for treating cancer
US20200123142A1 (en) Substituted Cyclohexylamine Compounds
WO2021189036A1 (en) Taf1 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190423

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200107